Metabolite raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-30. Anything still debated is marked as such rather than presented as settled.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Common for reference-grade material. |
| Solubility | Low in water | Dissolves in DMSO and some organic solvents. |
| Typical storage | -20 °C, desiccated | Protect from light and moisture. |
| Analytical method | LC-MS/MS | Used for trace detection in biological matrices. |
| Purity assessment | HPLC with UV detection | Often combined with NMR and mass spectrometry. |
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
=== Tenure === In 2018, Dingell introduced a law that would give the Consumer Product Safety Commission the authority to recall defective firearms. John Dingell was a key lawmaker who initially granted the firearms industry this exemption from the 1972 Consumer Product Safety Act that created the Consumer Product Safety Commission. In July 2019, Dingell voted against a House resolution introduced by Representative Brad Schneider opposing efforts to boycott the State of Israel and the Global Boycott, Divestment, and Sanctions Movement. The resolution passed 398–17. In April 2021, Dingell introduced the Recovering America's Wildlife Act of 2021, a bill that would provide funding for conserving and protecting endangered and threatened species, strategies to do so, and wildlife-related recreational activities. The bill passed the House by 230–190 on June 14, 2022. In 2023, Dingell was among 56 Democrats to vote in favor of H.Con.Res. 21, which directed President Joe Biden to remove U.S. troops from Syria within 180 days.
=== Antifungal properties === Capsaicin acts as an antifungal agent in four primary ways. First, capsaicin inhibits the metabolic rate of the cells that make up the fungal biofilm. This inhibits the area and growth rate of the fungus, since the biofilm creates an area where a fungus can grow and adhere to the chili in which capsaicin is present. Capsaicin also inhibits fungal hyphae formation, which impacts the amount of nutrients that the rest of the fungal body can receive. Thirdly, capsaicin disrupts the structure of fungal cells and the fungal cell membranes. This has consequential negative impacts on the integrity of fungal cells and their ability to survive and proliferate. Additionally, the ergosterol synthesis of growing fungi decreases in relation to the amount of capsaicin present in the growth area. This impacts the fungal cell membrane, and how it is able to reproduce and adapt to stressors in its environment.
==== As plaintiff ==== Monster Beverage Corporation has been criticized for its policy of indiscriminately suing companies and/or brands that use the word monster, the letter M, or the word beast in their marketing for trademark infringement, despite such trademarks being generally dissimilar or distinguishable from Monster's. The words monster and beast have existed in the English language since the 13th century, with the Latin letter M tracing back to the 7th century BC. By 2019, the company has initiated over a thousand trademark cases that have been reviewed by the US court system or US Patent and Trademark Office's (USPTO) Trademark Trial and Appeal Board, making them a poster child for "trademark bullying" which the USPTO defines as "a trademark owner that uses its trademark rights to harass and intimidate another business beyond what the law might be reasonably interpreted to allow." Examples of such lawsuits include the 2009 ones against Bevreview.com, a beverage review site that published an unfavorable review of the Monster Energy drink, Rock Art Brewery from Vermont that marketed a beer named "Vermonster", and the aquarium hobbyist site MonsterFishKeepers.com in 2012. The "Vermonster" case was even brought up by Senator Patrick Leahy in a study of problematic trademark litigation tactics. Monster Beverage dropped the lawsuit against the microbrewery due to the adverse publicity the lawsuit generated. In a four year case from 2015 to 2019, Monster sued Maple Leaf Sports & Entertainment (MLSE), the parent of the Toronto Raptors, and the NBA.
Sources: en.wikipedia.org
In the case of BPD, this necessitates the identification of at least four out of seven maladaptive traits, these being: emotional lability, anxiousness, separation insecurity, depressivity, impulsivity, risk-taking, and hostility, of which at least one must be of the three last mentioned. These traits have been found to correspond well to BPD as defined in the categorical model.
== Career == Sur joined the faculty of the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology (MIT) in 1986. In 1993, he was named professor of Neuroscience, and in 1997, head of the Department of Brain and Cognitive Sciences. He is currently the Newton Professor of Neuroscience and director of the Simons Center for the Social Brain at MIT. Sur is a pioneer in technology development for analyzing the function and structure of neurons and synapses in the live brain, and the study of brain plasticity and its mechanisms. His research involves experimental and computational approaches to study developmental plasticity in the developing brain, and dynamic changes in mature cortical networks during learning and information processing. His laboratory investigates fundamental principles governing how networks of the cerebral cortex are wired during development and are dynamically reorganized during learning. His group's discoveries have provided foundational concepts of how cortical circuits process information underlying perception, cognition, and goal-directed action.
XRD, FTIR, Raman, XPS, AFM, TEM, SEM/EDX, Thermogravimetric analysis etc. are some common techniques used to characterize GO samples. Experimental results of graphite/graphene oxide have been analyzed by calculation in detail. Since the distribution of oxygen functionalities on GO sheets is polydisperse, fractionation methods can be used to characterize and separate GO sheets on the basis of oxidation. Different synthesis methods give rise to different types of graphene oxide. Even different batches from similar oxidation methods can have differences in their properties due to variations in purification or quenching processes.
== Investors == In November 2012, Intarcia received $210M in preferred stock and debt financing from, The Baupost Group, Farallon Capital Management, New Enterprise Associates, New Leaf Venture Partners and Venrock Associates. Other Investors include Greenspring Associates, Alta Partners and Granite Venture Partners. In April 2014, Intarcia secured an additional $200M in financing. RA Capital led the round and was joined by new and existing investors. In April 2015, the company raised $225M in exchange for 1.5% of future global net sales of ITCA 650. In May 2016, Intarcia secured an additional $75M in financing to scale-up manufacturing and inventory in anticipation of ITCA 650s global launch. In September 2016, Intarcia raised an additional $215M in equity financing to prepare for the commercial launch of ITCA 650 in late 2017 and additional pipeline programs.
Sources: en.wikipedia.org
LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.
Reference material is usually kept cold, dry, and protected from light. Frozen aliquots reduce repeated freeze-thaw cycles.
No approved pharmaceutical product exists, so manufacturing and quality controls are not standardized. Products may contain different compounds or impurities.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.